Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke

This study is a multicenter, prospective, cohort study to observe the clinical efficacy and safety of edaravone dextrol in patients with acute ischemic stroke in a real-world setting.

Inclusion Criteria:Age≥18 years old；Clinically diagnosed as acute ischemic stroke；Time from symptom onset to admission≤14 days (symptom onset time is defined as last known well time)；Pre-stroke mRS ≤1；Have been informed of the content of the informed consent form and agree to participate.Exclusion Criteria:Acute intracranial hemorrhagic diseases confirmed by images: parenchymal hemorrhage, epidural hematoma, subdural hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc.Patients who are pregnant or lactating and who are planned to become pregnant within 90 days;Patients with severe renal failure (eGFR<30ml/min);Patients with concurrent malignancy or severe systemic disease with an estimated survival of less than 90 days;Patients with severe mental disorders or unable to complete the informed consent and follow-up due to dementia;Patients who are judged unsuitable for participation in the study.